Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Nat Med. 2015 Oct 26;21(11):1364–1371. doi: 10.1038/nm.3973

Figure 5. TP53 mutational status, localization of SOX9 and clinical outcome.

Figure 5

(a) Control vector (mCherry), or KRASG12D or TP53R175H expressing organoids co-stained for SOX9 (green) and KRAS or TP53 (red), DAPI, blue. Insets represent high-resolution images of representative organoids. (b) Quantification of nuclear SOX9 in mCherry- and TP53R175H-expressing pancreatic progenitor organoids. Graph summarizes results from three independent sets of experiments with over 50 structures counted in each experiment. ***P =< 0.001. (c) H&E and immunostaining for TP53 (P53, red) SOX9 (green) in normal pancreas and PDAC. Scale bars, 50 µm. (d) Representative images of chromogenic IHC staining showing nuclear, nuclear-cytoplasmic and cytoplasmic SOX9 staining (top panel). Samples with different SOX9 status scored for TP53 mutation status and expressed as percentage (lower panel). WT refers to Wild type. (e) Kaplan-Meier curve representing disease free survival (DFS) an overall survival (OS) of patients in cohort I with nuclear (green, N = 29), nuclear and cytoplasmic (red, N = 29), or cytoplasmic SOX9 (blue, N = 23). (f) Kaplan-Meier curve representing disease specific survival of patients in cohort II with cytoplasmic (black, N = 26) or nuclear SOX9 (red, N = 213).